Our loss-of-function and gain-of-function studies of DR3/TL1A suggest that the susceptibility of cancer cells to tubulin-targeting agents is determined by the combination expression of TL1A and its receptor DR3, offering some explanation for the tissue specificity of these drugs. The gene discussed is TNFRSF25; the disease is cancer.